Prostate Cancer - Results from #24440

Treatment of recurrent prostate cancer following radical prostatectomy: The radiation-oncologists point of view - Abstract November 8, 2012

[11C]Choline-PET/CT for outcome prediction of salvage radiotherapy of local relapsing prostate carcinoma - Abstract November 8, 2012

Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer - Abstract November 8, 2012

Robot-assisted radical prostatectomy in elderly patients : Surgical, oncological and functional outcomes - Abstract November 8, 2012

Erectile dysfunction after prostate three-dimensional conformal radiation therapy : Correlation with the dose to the penile bulb - Abstract November 8, 2012

Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare - Abstract November 8, 2012

Transperineal magnetic resonance image-targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer - Abstract November 8, 2012

Moving a randomized clinical trial into an observational cohort - Abstract November 8, 2012

Histopathology reports of findings of prostate needle biopsies: Individual treatment - Abstract November 8, 2012

Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy - Abstract November 8, 2012

A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease - Abstract November 8, 2012

Integration of immunotherapy into the management of advanced prostate cancer - Abstract November 8, 2012

Approach to prostate cancer in men older than 75 years : Active or passive? - Abstract November 6, 2012

Moderate hypofractionation and simultaneous integrated boost with volumetric modulated arc therapy (RapidArc) for prostate cancer : Report of feasibility and acute toxicity - Abstract November 6, 2012

Prostate-specific antigen nadir and time to prostate-specific antigen nadir following maximal androgen blockade independently predict prognosis in patients with metastatic prostate cancer - Abstract November 6, 2012

Cost of palliative radiation to the bone for patients with bone metastases secondary to breast or prostate cancer - Abstract November 6, 2012

Practical issues and pitfalls in staging tumors of the genitourinary tract - Abstract November 6, 2012

Long-term outcomes and prognostic factors in patients treated with intraoperatively planned prostate brachytherapy - Abstract November 6, 2012

Prognostic significance of circulating tumor cell count in patients with metastatic hormone-sensitive prostate cancer - Abstract November 6, 2012

Competing event risk stratification may improve the design and efficiency of clinical trials: Secondary analysis of SWOG 8794 - Abstract November 6, 2012

Page 1223 of 1435